Literature DB >> 8904619

The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.

J Wan1, H Xia, N He, Y Q Lu, H H Zhou.   

Abstract

1. The disposition of diazepam and desmethyldiazepam was studied in 21 healthy male Chinese subjects who were phenotyped with mephenytoin. Four poor metabolizers (PM) were identified by phenotyping with mephenytoin and by genotyping for CYP2C19. 2. Serum diazepam and desmethyldiazepam concentrations were measured by high performance liquid chromatography in samples drawn up to 24 days after administration. 3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs. 4. The mephenytoin S/R ratios were significantly correlated with the plasma half-lives of diazepam (r = 0.543, P < 0.05) and desmethyldiazepam (r = 0.522, P < 0.05), and with the clearance (r = -0.524, P < 0.05) of diazepam in 21 subjects. 5. These results are compatible with the conclusion that both diazepam and desmethyldiazepam are metabolized by cytochrome P450 CYP2C19 in the Chinese population. 6. The mephenytoin S/R ratios in nine EMs who drank alcohol frequently were significantly higher than those of seven EMs who were non-drinkers, but the plasma kinetics of diazepam and desmethyldiazepam were not significantly different between the two groups. The explanation for these finding is not clear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904619      PMCID: PMC2042686          DOI: 10.1046/j.1365-2125.1996.42712.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

2.  Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

3.  Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.

Authors:  Manu Jose; Jayanthi Mathaiyan; Shivanand Kattimani; Surendiran Adithan; Adithan Chandrasekaran
Journal:  Eur J Clin Pharmacol       Date:  2016-04-20       Impact factor: 2.953

4.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment.

Authors:  Nobuyoshi Ishii; Takeshi Terao; Yasuo Araki; Koji Hatano
Journal:  BMJ Case Rep       Date:  2013-11-22

Review 8.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

9.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.

Authors:  Su-Jun Lee
Journal:  Front Genet       Date:  2013-02-01       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.